PMDA drug package insert
リプレガル点滴静注用3.5mg
PMDA Prescription drug · 武田薬品工業株式会社 · package insert Feb 15, 2022
Key facts
| Brand names | リプレガル点滴静注用3.5mg |
|---|---|
| Nonproprietary names | アガルシダーゼ アルファ（遺伝子組換え） |
| Companies | 製造販売元／武田薬品工業株式会社 |
| Product type | Prescription drug |
| Therapeutic category | α-ガラクトシダーゼ酵素製剤 |
| Therapeutic category codes | 873959 |
| YJ codes | 3959410A1025 |
| Approval numbers | 21800AMY10136 |
| Package insert edition | 第1版 |
| Package insert date | Feb 15, 2022 |
| PMDA document key | 400256_3959410A1025_2 |
| PMDA company code | 400256 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: